Peer M. Schatz at the World Economic Forum Annual Meeting of the New Champions in 2009

Peer M. Schatz (born August 3, 1965) is a Swiss and Austrian entrepreneur and executive in the life sciences. Among other roles, he was the chief executive officer of QIAGEN N.V. where he over almost 30 years led QIAGEN's development from a startup to a global market and technology leader with over 5100 employees and to a market capitalization of over $10 billion.[1]

Early life and education

Schatz grew up in the United States and Switzerland. After his Matura (A-Levels/ university entrance diploma), Schatz studied business and social sciences at the University of St. Gallen, Switzerland. He graduated with a master's degree in finance in 1989 and obtained a Master of Business Administration (MBA) from the University of Chicago Graduate School in Business in 1990.

Career

Schatz worked in different positions for Sandoz AG and Computerland and participated in the foundation of startup companies in the computer and software trading industry in Europe and the United States.

In 1993, Schatz joined QIAGEN and paved the way for both the company's initial public offering at the Nasdaq in 1996 as the first German company ever and the subsequent listing at the Frankfurt Stock Exchange (Germany). He advanced QIAGEN's strategic focus on sample and assay technologies in the molecular diagnostics, applied testing, academic and pharmaceutical markets. During his time at QIAGEN, the company grew from $2 million in annual revenues to $1.5 billion in 2018.[2]

Schatz resigned as CEO October 7, 2019 and transitioned to the role of special advisor.[3] SEC filings list Schatz as the owner of a number of shares and rights on shares which represented about 3% of the outstanding shares of QIAGEN.

Schatz serves as a member of the Managing Board of PS Capital Management GmbH.

Other activities

He is chairman of the board of Resolve Biosciences GmbH[4] as well as of Centogene NV[5] and a member of the supervisory board of Siemens Healthineers AG.[6] and of the advisory board of HSBC Trinkaus & Burkhardt.[7] He previously held director positions of AdvaMedDx (U.S. in-vitro diagnostics industry organization) and ALDA (U.S. Life Science and Diagnostics Association).

From 2001 to 2011, Schatz served as a member of the German Corporate Governance Commission.

Personal life

Schatz is married to Nadine Schatz-Grandjean-Perrenoud-Contesse, a Swiss citizen and likewise an alumna of the University of St. Gallen. He is the son of famous biochemist Gottfried Schatz, who co-discovered mitochondrial DNA.

References

  1. ↑ "Siemens Healthineers".
  2. ↑ Ludwig Burger (8 October 2019), Qiagen CEO quits amid genetic sequencing U-turn, shares tumble Reuters.
  3. ↑ "QIAGEN announces CEO leadership transition".
  4. ↑ "Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis". 10 December 2020.
  5. ↑ "Supervisory Board".
  6. ↑ "Siemens Healthineers".
  7. ↑ Advisory Board HSBC Trinkaus & Burkhardt.

Sources

[1] [2]

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.